These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29284118)

  • 1. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
    Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
    Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
    Sung B; Kunnumakkara AB; Sethi G; Anand P; Guha S; Aggarwal BB
    Mol Cancer Ther; 2009 Apr; 8(4):959-70. PubMed ID: 19372569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
    Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
    Siveen KS; Mustafa N; Li F; Kannaiyan R; Ahn KS; Kumar AP; Chng WJ; Sethi G
    Oncotarget; 2014 Feb; 5(3):634-48. PubMed ID: 24504138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
    Berenson JR; Ma HM; Vescio R
    Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway.
    Song IS; Jeong YJ; Nyamaa B; Jeong SH; Kim HK; Kim N; Ko KS; Rhee BD; Han J
    BMB Rep; 2015 Oct; 48(10):571-6. PubMed ID: 25772758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
    Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
    Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H
    Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
    Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
    Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
    Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
    Yan W; Li R; He J; Du J; Hou J
    Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
    Salem K; Brown CO; Schibler J; Goel A
    Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Zou P; Kawada J; Pesnicak L; Cohen JI
    J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.